The FDA granted orphan designation to Sanofi US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Discover th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback